Calliditas Therapeutics Future Growth
Future criteria checks 6/6
Calliditas Therapeutics is forecast to grow earnings and revenue by 52.9% and 29.7% per annum respectively. EPS is expected to grow by 53.8% per annum. Return on equity is forecast to be 113.5% in 3 years.
Key information
52.9%
Earnings growth rate
53.8%
EPS growth rate
| Pharmaceuticals earnings growth | 27.6% |
| Revenue growth rate | 29.7% |
| Future return on equity | 113.5% |
| Analyst coverage | Good |
| Last updated | 10 Jun 2024 |
Recent future growth updates
Recent updates
Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics
May 28Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
Aug 18Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy
Jul 15Calliditas submits nefecon marketing authorisation application to the EMA
May 28Calliditas shares rise 10% as FDA grants priority review for Nefecon
Apr 28Calliditas Therapeutics reports Q3 results
Nov 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,434 | 2,024 | 3,040 | 3,065 | 6 |
| 12/31/2025 | 3,211 | 1,127 | 1,314 | 1,336 | 8 |
| 12/31/2024 | 1,876 | -62 | 284 | 315 | 8 |
| 3/31/2024 | 1,311 | -525 | -414 | -401 | N/A |
| 12/31/2023 | 1,207 | -466 | -447 | -435 | N/A |
| 9/30/2023 | 1,184 | -451 | -230 | -227 | N/A |
| 6/30/2023 | 1,150 | -292 | -292 | -290 | N/A |
| 3/31/2023 | 944 | -393 | -354 | -352 | N/A |
| 12/31/2022 | 803 | -412 | -314 | -311 | N/A |
| 9/30/2022 | 405 | -628 | -724 | -703 | N/A |
| 6/30/2022 | 343 | -608 | -634 | -611 | N/A |
| 3/31/2022 | 279 | -576 | -541 | -519 | N/A |
| 12/31/2021 | 229 | -500 | -484 | -462 | N/A |
| 9/30/2021 | 199 | -452 | -422 | -420 | N/A |
| 6/30/2021 | 0 | -600 | -490 | -490 | N/A |
| 3/31/2021 | 0 | -501 | -425 | -425 | N/A |
| 12/31/2020 | 1 | -433 | -309 | -309 | N/A |
| 9/30/2020 | 47 | -286 | -233 | -235 | N/A |
| 6/30/2020 | 47 | -198 | -64 | -48 | N/A |
| 3/31/2020 | 185 | -54 | -57 | -40 | N/A |
| 12/31/2019 | 185 | -33 | -87 | -71 | N/A |
| 9/30/2019 | 138 | -54 | -86 | -68 | N/A |
| 6/30/2019 | 138 | -35 | -166 | -166 | N/A |
| 3/31/2019 | N/A | -136 | -144 | -144 | N/A |
| 12/31/2018 | N/A | -132 | -128 | -128 | N/A |
| 9/30/2018 | N/A | -128 | -112 | -112 | N/A |
| 6/30/2018 | N/A | -115 | -114 | -114 | N/A |
| 3/31/2018 | N/A | -113 | -89 | -89 | N/A |
| 12/31/2017 | N/A | -87 | N/A | -68 | N/A |
| 12/31/2016 | N/A | -57 | N/A | -55 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CALT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: CALT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CALT is expected to become profitable in the next 3 years.
Revenue vs Market: CALT's revenue (29.7% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CALT's revenue (29.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CALT's Return on Equity is forecast to be very high in 3 years time (113.5%).